Mitochondrial Dysfunction

R&D

Partner Content

4th Mitochondrial Dysfunction Drug Development Summit

Uncover mitochondrial pathogenic mechanisms to show clinical efficacy for regulatory success

Events

Copy of Bella Mitochondria-Targeted Drug Development - LinkedIn (2)

Partner Content

2nd Mitochondria-Targeted Drug Development Summit

Therapies for mitochondrial dysfunction

News

Perlmutter's Eikon follows the IPO trail

Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Mitochondrial Dysfunction

Editor's Picks